Discover. Develop. Deliver.
Discover: A New Course
Instead of seeking drugs with incremental improvements, we pursue novel mechanisms that may change the course of a devastating disease.
Our discovery activities focus on three areas of unmet medical need
- .Our inflammation discovery platform targets small molecule modulation of eosinophil and basophil development, differentiation, and maturation, with potential relevance in a broad range of hemotalogical and immunological diseases.
- Our KCNQ2 discovery platform targets cellular excitability, which mediates the function of neurons in such persistently difficult diseases as epilepsy and neuropathic pain.
- Our mitochondrial discovery platform targets mechanisms of cellular bioenergetics, which play a key role in the degeneration of nerve cells in such intractable diseases as ALS, Parkinson’s, and other neurodegenerative diseases.
These programs bring together biologists and chemists with extensive experience in drug discovery at Bristol-Myers Squibb, Merck, Abbott, The National Institutes of Health, Harvard University, the University of Pittsburgh, and other leading institutions. We extend these capabilities through strategic research collaborations with industry and academic partners who share our passion for innovation.
Develop: In Less Time
Days count for a patient with a devastating disease and limited treatment options—which means days count in drug development. Our development team has a record of speed and efficiency in the drug development process. For example, the Knopp team advanced dexpramipexole for ALS from IND through Phase 1 and Phase 2 proof of concept in a little more than two years. We anticipate rapid advancement of early clinical-stage candidates from our preclinical pipeline and potentially from licensing activity.
Commercialization at Knopp means bridging the distance from laboratory to bedside and delivering safe, new medicines to patients as soon as possible. Our mission includes improving access to life-saving medicines.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.